gmp-manufacturing
(3)
Phillip Maderia
Phillip Maderia is the Chief Executive Officer of PranaX, a Houston-based regenerative-medicine biotech developing stem cell-derived exosome products at the Levit Green campus in the Texas Medical Center. He joined in March 2025 after four years running Lonza's exosome manufacturing site in Lexington, Massachusetts - the facility Lonza bought from Codiak BioSciences in 2021, where Maderia had previously served as VP of Manufacturing Operations. He is a career biomanufacturing operator with roots at Sanofi Genzyme and LFB-USA and roughly three decades of scale-up experience.
Syed T. Husain
Syed T. Husain is the Chairman and CEO of Made Scientific, a Princeton, New Jersey cell therapy contract development and manufacturing organization (CDMO) that he relaunched in 2025 out of the former BioCentriq. Backed by GC Corporation, the company runs a 60,000-square-foot GMP facility built to move autologous and allogeneic cell therapies from clinical batches to commercial supply. A chemical engineer by training who started on the manufacturing floor at Wyeth and Pfizer, Husain spent more than two decades in CDMO leadership at Lonza, Alcami, Emergent BioSolutions, and Resilience before taking the top job. He named the rebranded company MADE for Manufacturing and Development Excellence.
Shankar Ramaswamy
Shankar Ramaswamy is the co-founder, chairman and CEO of Kriya Therapeutics, a clinical-stage biopharmaceutical company building one-time gene therapies for common, highly prevalent chronic diseases rather than only rare ones. A physician by training who started his career evaluating drug candidates at Roivant Sciences and helping launch Axovant's record biotech IPO, he founded Kriya in 2019 and has since raised more than $600 million to vertically integrate gene therapy design, computational biology and in-house GMP manufacturing.